The Potential of Cyclodextrins as Novel Active Pharmaceutical Ingredients: A Short Overview

Cyclodextrins (CDs) are cyclic oligosaccharides of natural origin that were discovered more than 100 years ago. The peculiar cone-like conformation of the sugar ring, expressing a lipophilic cavity and a hydrophilic external surface, allows these substances to spontaneously complex poorly soluble co...

Full description

Bibliographic Details
Main Author: Massimiliano Pio di Cagno
Format: Article
Language:English
Published: MDPI AG 2016-12-01
Series:Molecules
Subjects:
Online Access:http://www.mdpi.com/1420-3049/22/1/1
id doaj-5776d045afae42bbbf260d5dfbf24ff5
record_format Article
spelling doaj-5776d045afae42bbbf260d5dfbf24ff52020-11-24T20:40:38ZengMDPI AGMolecules1420-30492016-12-01221110.3390/molecules22010001molecules22010001The Potential of Cyclodextrins as Novel Active Pharmaceutical Ingredients: A Short OverviewMassimiliano Pio di Cagno0Drug Transport and Delivery Research Group, Department of Pharmacy, University of Tromsø, The Arctic University of Norway, 9019 Tromsø, NorwayCyclodextrins (CDs) are cyclic oligosaccharides of natural origin that were discovered more than 100 years ago. The peculiar cone-like conformation of the sugar ring, expressing a lipophilic cavity and a hydrophilic external surface, allows these substances to spontaneously complex poorly soluble compounds in an aqueous environment. For more than 50 years, these substances have found applicability in the pharmaceutical and food industries as solubilizing agents for poorly soluble chemical entities. Nowadays, several research groups all over the world are investigating their potential as active pharmaceutical ingredients (APIs) for the treatment of several illnesses (e.g., hypercholesterolemia, cancer, Niemann-Pick Type C disease). The aim of this review is to briefly retrace cyclodextrins’ legacy as complexing agents and describe the current and future prospects of this class of chemical entities in pharmaceutics as new APIs.http://www.mdpi.com/1420-3049/22/1/1cyclodextrinsinclusion complexessolubilizing agentscytotoxic activityhypocholesterolemic agentsNiemann-Pick Type C disease treatment
collection DOAJ
language English
format Article
sources DOAJ
author Massimiliano Pio di Cagno
spellingShingle Massimiliano Pio di Cagno
The Potential of Cyclodextrins as Novel Active Pharmaceutical Ingredients: A Short Overview
Molecules
cyclodextrins
inclusion complexes
solubilizing agents
cytotoxic activity
hypocholesterolemic agents
Niemann-Pick Type C disease treatment
author_facet Massimiliano Pio di Cagno
author_sort Massimiliano Pio di Cagno
title The Potential of Cyclodextrins as Novel Active Pharmaceutical Ingredients: A Short Overview
title_short The Potential of Cyclodextrins as Novel Active Pharmaceutical Ingredients: A Short Overview
title_full The Potential of Cyclodextrins as Novel Active Pharmaceutical Ingredients: A Short Overview
title_fullStr The Potential of Cyclodextrins as Novel Active Pharmaceutical Ingredients: A Short Overview
title_full_unstemmed The Potential of Cyclodextrins as Novel Active Pharmaceutical Ingredients: A Short Overview
title_sort potential of cyclodextrins as novel active pharmaceutical ingredients: a short overview
publisher MDPI AG
series Molecules
issn 1420-3049
publishDate 2016-12-01
description Cyclodextrins (CDs) are cyclic oligosaccharides of natural origin that were discovered more than 100 years ago. The peculiar cone-like conformation of the sugar ring, expressing a lipophilic cavity and a hydrophilic external surface, allows these substances to spontaneously complex poorly soluble compounds in an aqueous environment. For more than 50 years, these substances have found applicability in the pharmaceutical and food industries as solubilizing agents for poorly soluble chemical entities. Nowadays, several research groups all over the world are investigating their potential as active pharmaceutical ingredients (APIs) for the treatment of several illnesses (e.g., hypercholesterolemia, cancer, Niemann-Pick Type C disease). The aim of this review is to briefly retrace cyclodextrins’ legacy as complexing agents and describe the current and future prospects of this class of chemical entities in pharmaceutics as new APIs.
topic cyclodextrins
inclusion complexes
solubilizing agents
cytotoxic activity
hypocholesterolemic agents
Niemann-Pick Type C disease treatment
url http://www.mdpi.com/1420-3049/22/1/1
work_keys_str_mv AT massimilianopiodicagno thepotentialofcyclodextrinsasnovelactivepharmaceuticalingredientsashortoverview
AT massimilianopiodicagno potentialofcyclodextrinsasnovelactivepharmaceuticalingredientsashortoverview
_version_ 1716826157104496640